Invitae (NYSE: NVTA) shares have plummeted more than 80% this year. The genetic testing company has grown revenue over the years, but it hasn't been able to turn that revenue into profit. Instead, ...

Late Friday, the U.S. FDA granted De Novo marketing authorization for the Invitae Common Hereditary Cancers Panel. The panel is the first of its kind to receive FDA marketing authorization. Invitae is ...

Invitae is a growth leader in genetic testing. The company is growing at full speed, and it has enormous room for expansion going forward. Lack of profitability and share dilution are the main ...

Invitae Corporation faces significant challenges in addressing its liquidity concerns. Invitae has entered into an Asset Purchase Agreement with Natera, involving the sale of specific assets in the ...

Within the last quarter, Invitae (NYSE:NVTA) has observed the following analyst ratings: These 5 analysts have an average price target of $7.2 versus the current price of Invitae at $2.675, implying ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

Invitae (NYSE:NVTA) stock is in the spotlight today after the company announced a collaboration with Simons Searchlight. Simons is an international research program that focuses on rare genetic ...